

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

FIRST NAMED INVENTOR CONFIRMATION NO. APPLICATION NO. FILING DATE ATTORNEY DOCKET NO. 09/931,325 08/15/2001 Ashley J. Birkett ICC-103.1 US 83502 3946 EXAMINER 24628 01/28/2004 WELSH & KATZ, LTD LUCAS, ZACHARIAH 120 S RIVERSIDE PLAZA ART UNIT PAPER NUMBER 22ND FLOOR CHICAGO, IL 60606 1648

DATE MAILED: 01/28/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action	Application No.	Applicant(s)
	09/931,325	BIRKETT, ASHLEY J.
	Examiner	Art Unit
	Zachariah Lucas	1648
The MAILING DATE of this communication appears on the cover sheet with the correspondence address		
THE REPLY FILED 22 December 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.		
PERIOD FOR REPLY [check either a) or b)]		
a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.		
2. The proposed amendment(s) will not be entered because:		
(a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below);		
(b) ☐ they raise the issue of new matter (see Note below);		
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or		
(d) they present additional claims without canceling a corresponding number of finally rejected claims.		
NOTE: See Continuation Sheet.		
3. Applicant's reply has overcome the following rejection(s):		
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).		
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:		
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.		
7.⊠ For purposes of Appeal, the proposed amendment(s) a)⊠ will not be entered or b)□ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected:		
Claim(s) withdrawn from consideration:		
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.		
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)		
10. Other:		

TECHNOLOGY CENTER 1600

Continuation of 2. NOTE: In the After-Final amendment filed on December 22, 2003, the Applicant indicated amendments of the rejected claims such that the claims would be limited to the claimed chimeric protein wherein the Plasmodium antigens were antigens againt P. falciparum infection. The Applicant apparently read the explanation of the rejection in the Final action as indicating that claim language reading on any P. falciparum epitope would be allowable. Such was not the case. As indicated (e.g.) on page 7 of that action, the Examiner agreed that the unexpected results were demonstrated with respect to antigens comprising the NANP repeat from the P. falciparum CS protein. However, there is no indication that the unexpected results would occur using any P. falciparum B antigen. Nonetheless, the amendments would, if entered, avoid the outstanding prior art rejection because the references cited in the rejection do not teach other P. falciparum B antigens than the NANP repeat, thereby meriting further examination of the amendment is denied entry.

2